28 Jun MaxCyte
Sarah Meeks, Ph.D., Senior Vice President, Business Development
April 13 | 1:45pm | Dark Horse Consulting Ballroom
Rockville, MD
(NASDAQ: MXCT)
MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development, and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and freedom to operate.
